[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623770":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":56,"collaborators":25,"id":58,"slug":25,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"GLK-221 Ophthalmic Solution","EXPERIMENTAL","GLK-221 Ophthalmic Solution administered topically twice daily to both eyes",[13],"Drug: GLK-221 Ophthalmic Solution",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo Ophthalmic Solution administered topically twice daily to both eyes",[19],"Drug: Placebo Ophthalmic Solution",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","GLK-221 Ophthalmic Solution administered twice daily to both eyes",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo Ophthalmic Solution","Placebo Ophthalmic Solution administered twice daily to both eyes",[15],[31],{"name":32,"affiliation":5,"role":33},"Study Director, MD","STUDY_DIRECTOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Study Manager","CONTACT","949-739-8749","ClinicalResearch@Glaukos.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Glaukos Clinical Study Site","RECRUITING","Westerville","Ohio","43082","United States",{"type":49,"coordinates":50},"Point",[51,52],-82.92907,40.12617,{"lat":52,"lon":51},[55],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":25},{"type":57,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100623770",false,"NCT07400952","Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus","Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus","Inclusion Criteria:\n\n* Be ≥ 18 and ≤ 55 years of age\n* Diagnosis of keratoconus in the study eye\n\nExclusion Criteria:\n\n* Pregnant, lactating or planning a pregnancy\n* Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial","ALL","18 Years","55 Years",{"count":68,"type":69},100,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.",[75],"Keratoconus",[75],"2026-02-03",{"date":79,"type":80},"2026-02-10","ACTUAL",{"date":82,"type":80},"2025-12-23",{"date":84,"type":69},"2027-04",{"name":5,"class":6},1]